A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
出版年份 2013 全文链接
标题
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 161, Issue 5, Pages 688-694
出版商
Wiley
发表日期
2013-04-10
DOI
10.1111/bjh.12332
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells
- (2012) Ariel Amaru Calzada et al. EXPERIMENTAL HEMATOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells
- (2010) X. Wang et al. BLOOD
- Polycythemia vera-associated pruritus and its management
- (2010) Kamal S. Saini et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Janus Kinase 2: An Epigenetic 'Writer' that Activates Leukemogenic Genes
- (2010) J. He et al. Journal of Molecular Cell Biology
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
- (2009) G. Barosi et al. BLOOD
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
- (2009) Giovanni Barosi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
- (2009) Alessandro M. Vannucchi et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
- (2009) Mark A. Dawson et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation